Shares of Indivior Plummet on Suboxone Patent Ruling
November 20 2018 - 11:20AM
Dow Jones News
By Carlo Martuscelli
Shares of Indivior PLC (INDV.LN) plummeted on Tuesday after a
U.S. court overturned an injunction against Dr. Reddy's
Laboratories Ltd. (500124.BY) preventing the sale of a generic
version of Indivior's Suboxone opioid-addiction treatment.
The drugmaker said despite the result it will continue to pursue
patent-infringement cases against Dr. Reddy's to protect its
Suboxone patent portfolio.
"The company is in the process of interpreting the ruling in its
entirety and will issue a statement on its implications once this
review has been completed," Indivior said.
In July, the FTSE 250-listed pharmaceutical company was granted
an injunction preventing Dr. Reddy's from selling its own generic
version of the opioid treatment in the U.S. on the grounds of
copy-right infringement. This was subsequently appealed by the
Indian company.
Shares of Indivior at 1540 GMT were down 76.85 pence, or 38%,
126.80 pence.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
November 20, 2018 11:05 ET (16:05 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024